Faculty Opinions recommendation of The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol.

Author(s):  
Henry Burger
1982 ◽  
Vol 48 (03) ◽  
pp. 283-285 ◽  
Author(s):  
Jørgen Jespersen ◽  
Cornelis Kluft

SummaryDeterminations by immunologic methods of histidine-rich glycoprotein (HRG) and plasminogen, were made in plasma samples collected during one normal or hormone induced cycle in 15 young, normal women and in 11 women using oral contraceptives with 30 μg ethinyl estradiol and 150 μg levo-norgestrel. The hormone group showed an increase in plasminogen level to about 150% of normal, while the concentration of HRG was decreased to about 75% of normal. This resulted in a considerable relative increase in the concentration of free plasminogen in the hormone group (calculated from the equilibrium: HRG·plasminogen ⇌ HRG + plasminogen, using KD = 1.0 μM), representing a doubling of that in the normal group. Hence, more plasminogen is available for binding to fibrin and activation in the hormone group.


2021 ◽  
Vol 19 (1) ◽  
pp. 149-158
Author(s):  
O.A. Limanova ◽  
◽  
L.E. Fedotova ◽  
O.A. Gromova ◽  
◽  
...  

This article discusses the problem of drug interactions between combined oral contraceptives on the example of Belara® (30 μg of ethinyl estradiol + 2 mg of chlormadinone acetate; Gedeon Richter, Hungary) and medications recommended for the treatment of new coronavirus infection (COVID-19) and concomitant disorders at the pharmacodynamic and pharmacokinetic levels with an assessment of the efficacy and safety of therapy for females. We described safe, potentially dangerous, and dangerous combinations of these drugs. Key words: new coronavirus infection (CAVID-19), combined oral contraceptives, antiviral drugs, antibacterial drugs, antiinflammatory drugs, anticoagulants, migraine drugs, antihypertensive drugs, oral hypoglycemic drugs, essential micronutrients, pharmacodynamic and pharmacokinetic interactions


2011 ◽  
Vol 8 (5) ◽  
pp. 1478-1485 ◽  
Author(s):  
Salvatore Caruso ◽  
Marco Iraci Sareri ◽  
Carmela Agnello ◽  
Mattea Romano ◽  
Lucia Lo Presti ◽  
...  

PEDIATRICS ◽  
1980 ◽  
Vol 66 (4) ◽  
pp. 644-645
Author(s):  
Janet P. Realini

I read with interest the excellent review by Drs Greydanus and McAnarney.1 Several of their points concerning combined oral contraceptives deserve discussion, however. The relative potencies of the progestins and estrogens contained in oral contraceptives are controversial. Progestin potency is difficult to measure reliably, and comparisons among progestins can be misleading.2 While animal studies have suggested that mestranol is a weaker estrogen than ethinyl estradiol, a study of human ovulation inhibition suggested that ethinyl estradiol may be weaker than mestranol.3


Sign in / Sign up

Export Citation Format

Share Document